Spots Global Cancer Trial Database for Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Official Title: Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
Study ID: NCT00112658
Conditions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective as first-line therapy in treating pancreatic cancer. PURPOSE: This randomized phase II/III trial is studying how well combination chemotherapy works as first-line therapy in treating patients with metastatic pancreatic cancer.
Detailed Description: OBJECTIVES: Primary * Compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with oxaliplatin, irinotecan, leucovorin calcium, and fluorouracil vs gemcitabine as first-line chemotherapy. (Phase II) * Compare the survival of patients treated with these regimens. (Phase III) Secondary * Compare the toxicity of these regimens in these patients. * Compare progression-free survival of patients treated with these regimens. (Phase III) * Compare the overall response rate in patients treated with these regimens. (Phase III) * Compare quality of life of patients treated with these regimens. (Phase III) OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oxaliplatin IV over 2 hours, irinotecan IV over 1½ hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days. * Arm II: Patients receive gemcitabine IV on days 1, 8, 15, 22, 29, 36, and 43. Beginning on day 57, patients receive gemcitabine IV once weekly for 3 weeks (days 57, 64, and 71). Courses repeat every 28 days. PROJECTED ACCRUAL: A total of 348 patients (88 for phase II and 260 for phase III) will be accrued for this study.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Hospitalier Universitaire d'Amiens, Amiens, , France
Hopital Duffaut, Avignon, , France
Centre Hospitalier General, Belfort, , France
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, , France
Hopital Avicenne, Bobigny, , France
Hopital Saint Andre, Bordeaux, , France
Institut Bergonie, Bordeaux, , France
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, , France
Centre Hospitalier Docteur Duchenne, Boulogne Sur Mer, , France
Hopital Ambroise Pare, Boulogne-Billancourt, , France
CHU de Caen, Caen, , France
Centre Regional Francois Baclesse, Caen, , France
Centre Jean Perrin, Clermont-Ferrand, , France
CHR Clermont Ferrand, Hotel Dieu, Clermont-Ferrand, , France
Hopitaux Civils de Colmar, Colmar, , France
Centre Hospitalier Universitaire Henri Mondor, Creteil, , France
Hopital Du Bocage, Dijon, , France
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, , France
Centre Hospitalier Intercommunal St. Aubin les Elbeuf, Elbeuf, , France
Clinique Saint Vincent, Epernay, , France
Centre Hospitalier Departemental, La Roche Sur Yon, , France
CMC Les Ormeaux, Le Havre, , France
Centre Oscar Lambret, Lille, , France
Hopital Saint Vincent de Paul, Lille, , France
Polyclinique des Quatre Pavillons, Lormont, , France
Hopital de la Croix Rousse, Lyon, , France
Centre Leon Berard, Lyon, , France
Hopital Edouard Herriot - Lyon, Lyon, , France
Hopital Ambroise Pare, Marseille, , France
CHU de la Timone, Marseille, , France
CHU Nord, Marseille, , France
Hopital Notre-Dame de Bon Secours, Metz, , France
Centre Hospitalier General de Mont de Marsan, Mont-de-Marsan, , France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, , France
Centre Regional Rene Gauducheau, Nantes-Saint Herblain, , France
CHR D'Orleans - Hopital de la Source, Orleans, , France
Hopital Bichat - Claude Bernard, Paris, , France
Hopital Saint Michel, Paris, , France
Centre Hospitalier de Perpignan, Perpignan, , France
Centre Hospitalier Lyon Sud, Pierre Benite, , France
Institut Jean Godinot, Reims, , France
CHU - Robert Debre, Reims, , France
Centre Eugene Marquis, Rennes, , France
Hopital Charles Nicolle, Rouen, , France
Clinique Armoricaine De Radiologie, Saint Brieuc, , France
Centre Rene Huguenin, Saint Cloud, , France
Clinique Charcot, Sainte Foy Les Lyon, , France
Centre Hospitalier de Semur en Auxois, Semur en Auxois, , France
Centre Paul Strauss, Strasbourg, , France
Hopital Universitaire Hautepierre, Strasbourg, , France
Centre Hospitalier de Tarbes, Tarbes, , France
Institut Claudius Regaud, Toulouse, , France
CHU de Tours, Tours, , France
Centre Alexis Vautrin, Vandoeuvre-les-Nancy, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Name: Thierry Conroy, MD
Affiliation: Centre Alexis Vautrin
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
